CAY10471 racemic

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531655

CAS#: 844639-57-2 (racemic)

Description: CAY 10471 is a potent, highly selective CRTH2/DP 2 receptor antagonist. CAY10471 binds to the human CRTH2/DP2, DP1, and TP receptors with Ki values of 0.6, 1200, and >10,000 nM. Cat#531655 is a racemic mixture of CAY10471.

Chemical Structure

CAY10471 racemic
CAS# 844639-57-2 (racemic)

Theoretical Analysis

MedKoo Cat#: 531655
Name: CAY10471 racemic
CAS#: 844639-57-2 (racemic)
Chemical Formula: C21H21FN2O4S
Exact Mass: 416.1206
Molecular Weight: 416.47
Elemental Analysis: C, 60.56; H, 5.08; F, 4.56; N, 6.73; O, 15.37; S, 7.70

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 627865-18-3 (rotation +)   844639-57-2 (racemic)  

Synonym: CAY 10471; CAY10471; CAY-10471; TM30089; TM-30089; TM 30089

IUPAC/Chemical Name: 3-[[(4-fluorophenyl)sulfonyl]methylamino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid


InChi Code: InChI=1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)

SMILES Code: O=C(O)CN1C2=C(C3=C1C=CC=C3)CC(N(S(=O)(C4=CC=C(F)C=C4)=O)C)CC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 416.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Ito H, Yan X, Nagata N, Aritake K, Katsumata Y, Matsuhashi T, Nakamura M, Hirai H, Urade Y, Asano K, Kubo M, Utsunomiya Y, Hosoya T, Fukuda K, Sano M. PGD2-CRTH2 pathway promotes tubulointerstitial fibrosis. J Am Soc Nephrol. 2012 Nov;23(11):1797-809. doi: 10.1681/ASN.2012020126. PubMed PMID: 22997255; PubMed Central PMCID: PMC3482731.

2: Yue L, Durand M, Lebeau Jacob MC, Hogan P, McManus S, Roux S, de Brum-Fernandes AJ. Prostaglandin D2 induces apoptosis of human osteoclasts by activating the CRTH2 receptor and the intrinsic apoptosis pathway. Bone. 2012 Sep;51(3):338-46. doi: 10.1016/j.bone.2012.06.003. PubMed PMID: 22705147.

3: Nakahigashi K, Doi H, Otsuka A, Hirabayashi T, Murakami M, Urade Y, Zouboulis CC, Tanizaki H, Egawa G, Miyachi Y, Kabashima K. PGD2 induces eotaxin-3 via PPARγ from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol. 2012 Feb;129(2):536-43. doi: 10.1016/j.jaci.2011.11.034. Erratum in: J Allergy Clin Immunol. 2014 Feb;133(2):604. Zouboulis, Christos C [added]. PubMed PMID: 22206772.

4: Ebersberger A, Natura G, Eitner A, Halbhuber KJ, Rost R, Schaible HG. Effects of prostaglandin D2 on tetrodotoxin-resistant Na+ currents in DRG neurons of adult rat. Pain. 2011 May;152(5):1114-26. doi: 10.1016/j.pain.2011.01.033. PubMed PMID: 21345590.

5: Hatanaka M, Shibata N, Shintani N, Haba R, Hayata A, Hashimoto H, Baba A. 15d-prostaglandin J2 enhancement of nerve growth factor-induced neurite outgrowth is blocked by the chemoattractant receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2) antagonist CAY10471 in PC12 cells. J Pharmacol Sci. 2010;113(1):89-93. PubMed PMID: 20424389.

6: Satarug S, Wisedpanichkij R, Takeda K, Li B, Na-Bangchang K, Moore MR, Shibahara S. Prostaglandin D2 induces heme oxygenase-1 mRNA expression through the DP2 receptor. Biochem Biophys Res Commun. 2008 Dec 19;377(3):878-83. doi: 10.1016/j.bbrc.2008.10.094. PubMed PMID: 18957281.

7: Schuligoi R, Sedej M, Waldhoer M, Vukoja A, Sturm EM, Lippe IT, Peskar BA, Heinemann A. Prostaglandin H2 induces the migration of human eosinophils through the chemoattractant receptor homologous molecule of Th2 cells, CRTH2. J Leukoc Biol. 2009 Jan;85(1):136-45. doi: 10.1189/jlb.0608387. PubMed PMID: 18835884.